R
Ryoko Yamasaki
Researcher at Jichi Medical University
Publications - 76
Citations - 770
Ryoko Yamasaki is an academic researcher from Jichi Medical University. The author has contributed to research in topics: Hematopoietic stem cell transplantation & Transplantation. The author has an hindex of 12, co-authored 72 publications receiving 583 citations.
Papers
More filters
Journal ArticleDOI
Antibiotic prophylaxis in hematopoietic stem cell transplantation. A meta-analysis of randomized controlled trials.
Shun Ichi Kimura,Yu Akahoshi,Hirofumi Nakano,Tomotaka Ugai,Hidenori Wada,Ryoko Yamasaki,Yuko Ishihara,Koji Kawamura,Kana Sakamoto,Masahiro Ashizawa,Miki Sato,Kiriko Terasako-Saito,Hideki Nakasone,Misato Kikuchi,Rie Yamazaki,Shinichi Kako,Junya Kanda,Aki Tanihara,Junji Nishida,Yoshinobu Kanda +19 more
TL;DR: Systemic antibiotic prophylaxis successfully reduced the incidence of infection and there was no significant impact on mortality in hematopoietic stem cell transplantation recipients, according to a meta-analysis.
Journal ArticleDOI
Risk factors for pre- and post-engraftment bloodstream infections after allogeneic hematopoietic stem cell transplantation.
Misato Kikuchi,Yu Akahoshi,Hirofumi Nakano,Tomotaka Ugai,Hidenori Wada,Ryoko Yamasaki,Kana Sakamoto,Koji Kawamura,Yuko Ishihara,Miki Sato,Masahiro Ashizawa,Kiriko Terasako-Saito,Shun-ichi Kimura,Rie Yamazaki,Junya Kanda,Shinichi Kako,Junji Nishida,Yoshinobu Kanda +17 more
TL;DR: Bloodstream infections are frequently observed after allogeneic hematopoietic stem cell transplant (HSCT), and could cause morbidity and mortality.
Journal ArticleDOI
Prophylactic role of long-term ultra-low-dose acyclovir for varicella zoster virus disease after allogeneic hematopoietic stem cell transplantation.
Koji Kawamura,Hidenori Wada,Ryoko Yamasaki,Yuko Ishihara,Kana Sakamoto,Masahiro Ashizawa,Miki Sato,Tomohito Machishima,Kiriko Terasako,Shun Ichi Kimura,Misato Kikuchi,Hideki Nakasone,Rie Yamazaki,Junya Kanda,Shinichi Kako,Aki Tanihara,Junji Nishida,Yoshinobu Kanda +17 more
TL;DR: This study shows that long-term ultra-low-dose acyclovir appears to be effective for preventing VZV disease, especially disseminated V zoster virus disease, after allogeneic HSCT, but additional strategies such as the administration of varicella vaccine may be needed to eradicate VzV disease.
Journal ArticleDOI
Low-dose acyclovir prophylaxis for the prevention of herpes simplex virus disease after allogeneic hematopoietic stem cell transplantation.
Koji Kawamura,Hidenori Wada,Ryoko Yamasaki,Yuko Ishihara,Kana Sakamoto,Masahiro Ashizawa,Miki Sato,Tomohito Machishima,Kiriko Terasako,Shun-ichi Kimura,Misato Kikuchi,Hideki Nakasone,Rie Yamazaki,Junya Kanda,Shinichi Kako,Aki Tanihara,Junji Nishida,Yoshinobu Kanda +17 more
TL;DR: Low‐dose ACV (200 mg/day) has been shown to prevent varicella zoster virus reactivation in the middle and late phases of HSCT.
Journal ArticleDOI
Low‑dose acyclovir prophylaxis for the prevention of herpes simplex virus and varicella zoster virus diseases after autologous hematopoietic stem cell transplantation
Koji Kawamura,Jin Hayakawa,Yu Akahoshi,Naonori Harada,Hirofumi Nakano,Kazuaki Kameda,Tomotaka Ugai,Hidenori Wada,Ryoko Yamasaki,Yuko Ishihara,Kana Sakamoto,Masahiro Ashizawa,Miki Sato,Kiriko Terasako-Saito,Shun Ichi Kimura,Misato Kikuchi,Hideki Nakasone,Rie Yamazaki,Junya Kanda,Shinichi Kako,Aki Tanihara,Junji Nishida,Yoshinobu Kanda +22 more
TL;DR: It is suggested that low-dose acyclovir prophylaxis may be effective for preventing HSV and VZV disease after auto-HCT.